ASSERTIO HOLDINGS INC (ASRT) 6.26 +0.26 (+4.33%)
6.26 +0.26 (+4.33%)
US04546C2052 - Common Stock - Premarket: 6.34 +0.08 (+1.28%)
ASSERTIO HOLDINGS INC6.26
NASDAQ:ASRT (3/28/2023, 7:11:12 PM)+0.26 (+4.33%)
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. The Company’s commercial portfolio of branded products focuses on three areas: neurology, rheumatology, and pain and inflammation. Its primary marketed products include INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Otrexup (methotrexate) injection for subcutaneous use, Sympazan (clobazam) oral film, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipso (diclofenac potassium) Liquid filled capsules. Its other commercially available products include OXAYDO (oxycodone HCI, USP) tablets for oral use. INDOCIN (indomethacin) Suppositories are nonsteroidal anti-inflammatory drug (NSAID), indicated for moderate to severe rheumatoid arthritis, including acute flares of chronic diseases, moderate to severe ankylosing spondylitis, acute gouty arthritis and others.
Company Info
ASSERTIO HOLDINGS INC
100 S. Saunders Road, Suite 300
Lake Forest ILLINOIS 60045
P: 12244197106.0
CEO: Daniel A. Peisert
Employees: 30
Website: https://www.assertiotx.com/
ASRT News
21 days ago - Seeking AlphaAssertio Therapeutics Non-GAAP EPS of $0.32 beats by $0.12, revenue of $50.35M beats by $2.91M (NASDAQ:ASRT)Assertio Therapeutics press release (ASRT): Q4 Non-GAAP EPS of $0.32 beats by $0.12.Revenue of $50.35M (+51.1% Y/Y) beats by $2.91M.Adjusted EBITDA increased to $33.4 million,...
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA...
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical...
23 days ago - InvestorPlace7 Thrilling Stocks to Buy for Aggressive InvestorsSometimes you need to be aggressive to unlock the best returns for your portfolio. Just be smart when looking for the best stocks to buy.
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering...
a month ago - Seeking AlphaAssertio sees Q4 adjusted earnings of $0.31-$0.32 (NASDAQ:ASRT)Assertio (ASRT) has reported prelim net product sales of $49M-$50M (vs. $46.90M estimated) for its fourth quarter, representing an year-over-year growth of at least 54%
ASRT Twits
Here you can normally see the latest stock twits on ASRT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
